scPharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• scPharmaceuticals Inc SCPH.OQ reported a quarterly adjusted loss of 35 cents​​ per share for the quarter ended December 31, identical to the same quarter last year. The mean expectation of six analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -49 cents to -26 cents per share.

• Revenue rose 99.3% to $12.15 million from a year ago; analysts expected $12.08 million.

• scPharmaceuticals Inc's reported EPS for the quarter was a loss of 35 cents​.

• The company reported a quarterly loss of $18.85 million.

• scPharmaceuticals Inc shares had fallen by 13.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for scPharmaceuticals Inc is $17.00

This summary was machine generated from LSEG data March 19 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)